Demand for power generation equipment and ongoing infrastructure spending support the buy case. The company faces notable cost increases due to tariff actions and is struggling with pricing.

As the rise of artificial intelligence continues, companies operating in this space or relying on the technology are finding that they have two inextricable needs: data centers that can run and ...

The stock is up more than 200% in September as Datavault's focus on AI-driven data management, cryptocurrency and Web3 monetization position it squarely in the middle of very hot sectors. Datavault AI ...

Stock-split euphoria has played a role in sending the benchmark S&P 500 to new heights. An industry titan with macro tailwinds and an enviable share repurchase program is ripe for the picking by ...

Despite millions spent on financial software, many finance teams still rely on Excel to close their books and reconcile numbers while preparing them for audit. Two former Microsoft executives view it ...

Before joining Investopedia, David Marino-Nachison was an editor at The Wall Street Journal focused mainly on daily markets and investing news. He also worked on The Journal’s publishing desk; as a ...

Bill McColl has 25+ years of experience as a senior producer and writer for TV, radio, and digital media leading teams of anchors, reporters, and editors in creating news broadcasts, covering some of ...

A new Agent Mode comes to Office apps today, alongside an Office Agent in Copilot chat. is a senior editor and author of Notepad, who has been covering all things Microsoft, PC, and tech for over 20 ...

European vacation destinations will soon require travelers to have prints of their fingers taken as well as photos upon arrival. France, Italy, Portugal, the United Kingdom and 25 other countries will ...

Although the weather isn’t quite cooperating with the onset of autumn just yet, all the fun things about this season are ramping up, including this year’s Georgia State Fair. This has become a state ...

Larimar Therapeutics Inc. (NASDAQ: LRMR) is trading lower on Monday after the company released data from the ongoing long-term open-label (OL) study evaluating daily subcutaneous 25 mg and 50 mg ...